Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Metabolic Accelerator*
Phase 2 orforglipron data demonstrated 14.7% body weight reduction at 45mg without food or water requirements, and the addressable patient expansion is estimated to grow the anti-obesity medication market by 180 million new prescription patients between 2027 and 2032
Japan clinically labels "obesity" at BMI25, so the eligible pool is larger than the BMI30 headline suggests, but still far below USA levels
Until then, the obesity exclusion remains in effect
US$ 23.41
US$ 26.92
US$ 27.88
